Alvotech (ALVO) EPS (Weighted Average and Diluted) (2023 - 2024)
Alvotech (ALVO) reported EPS (Weighted Average and Diluted) of -$242863.7 for Q2 2024, up 30.56% on a YoY basis from -$186015.8 in Q3 2023, and up 30.56% quarter-over-quarter from -$349749.8 in Q2 2023.
Alvotech (ALVO) EPS (Weighted Average and Diluted) (2023 - 2024) Analysis & Trends
Alvotech has reported EPS (Weighted Average and Diluted) for 2 years, with the latest figure at -$242863.7 in Q2 2024.
- For the quarter ending Q2 2024, EPS (Weighted Average and Diluted) rose 30.56% year-over-year to -$242863.7; the trailing twelve-month figure through Jun 2024 stood at -$242863.7 (up 30.56% YoY), and the FY2024 full-year result was -$0.87, up 64.2% from the prior year.
- EPS (Weighted Average and Diluted) for Q2 2024 stood at -$242863.7, up from -$349749.8 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$242863.7 in Q2 2024, with the low at -$349749.8 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Alvotech | 12.16 Mn | -160.20 Mn | -22.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -242,863.66 |
| Jun 30, 2023 | -349,749.85 |